| INTRODUCTION
Lysergic acid diethylamide (LSD) is a psychoactive substance that alters states of consciousness and perception. Its psychedelic effects made it popular as a recreational drug, especially in the 1960s and 1970s, but LSD is still widely used today. 1 In addition, LSD has been reintroduced in psychiatric research [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and investigated as an adjunct to psychotherapy. 17, 18 Therefore, information about its metabolism and pharmacokinetics after controlled intake has received increasing interest. Doses that were used in recent clinical studies ranged from 75 μg, i.v., [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] to 200 μg, p.o., [12] [13] [14] [15] 19 resulting in low blood and urine concentrations. 12 , 20 Dolder et al. and Steuer et al. recently showed that LSD and its main urinary metabolite 2-oxo-3-hydroxy-LSD
(O-H-LSD) were detectable in plasma after controlled intake of 200 μg LSD in 16 healthy subjects 12, 20 and clinical toxicological cases of acute LSD overdose. 21 Studies of in vitro metabolism have further identified lysergic acid monoethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), 2-oxo-LSD, nor-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD as glucuronides, 22, 23 but no systematic information is available regarding their presence in human plasma after controlled intake of LSD. However, recent investigations confirmed the presence of 2-oxo-LSD and 13/14-hydroxy-LSD (glucuronides)
in plasma samples after controlled intake of 200 μg LSD. 20 The aim of this study was to develop a sensitive turboflow liquid chromatography tandem mass spectrometry (LC-MS/MS) method to quantify LSD, iso-LSD, O-H-LSD, and nor-LSD and potentially identify LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD (glucuronides) in human plasma samples. The method was developed using a triple-stage quadrupole LC-MS/MS instrument in selected reaction monitoring (SRM) mode after atmospheric pressure ionization (APCI).
Our method was established and successfully applied to the analysis of plasma samples from healthy volunteers after the intake of 100 μg LSD in a controlled clinical study. 
| MATERIALS AND METHODS

| Chemicals and reagents
| LC-MS/MS analysis
| Equipment
The HPLC system (Transcend TLX1 HPLC; Thermo Scientific, Basel, Switzerland) consisted of two Accela 1250 pumps for loading and eluting. The autosampler and sample extraction system were controlled by the Aria MX 2.1 software (Thermo Scientific). A cyclone P turboflow column (Thermo Scientific) was used for extraction, and a
Zorbax Eclipse XDB-C8 column (Agilent, Santa Clara, CA, USA) was used for chromatographic separation. The online extraction system was coupled to a TSQ Endura triple-stage mass spectrometer (Thermo Scientific) using APCI in positive mode because of its better performance with regard to matrix effects. 
| Mass spectrometry conditions
The positive ion discharge current was set to 5 μA. The vaporizer temperature was optimized to 400°C. Sheath and auxiliary gas provided the best results, with flow rates of 15 and 5 arbitrary units, respectively. The temperature of the ion transfer tube was set to 300°C. The system was tuned and optimized for the detection of LSD.
LSD and its metabolites were detected using SRM of the two to three most intense ion transitions. Analytes were identified when quantifier and qualifier ions were present within the given retention time.
Structures, transitions, and respective collision energies are shown in 
| Standard solutions
Stock solutions that contained 100 μg/mL LSD, 100 μg/mL LSD-d 3 ,
10 μg/mL iso-LSD, 10 μg/mL O-H-LSD, or 10 μg/mL nor-LSD in acetonitrile were prepared and stored in light-protected brown glass vials at −20°C. All of the solutions were prepared in duplicate to have different sets for quality control (QC) and calibration samples. Working solutions of each analyte at 0.1 μg/mL in purified water/acetonitrile were used for the preparation of QC and calibration samples and matrix and selectivity experiments. Because of the instability of LSD and to minimize possible degradation by various freeze-thaw cycles, 1 mL aliquots of stock and working solutions were prepared.
| Sample preparation
Study samples were sorted according to drug condition (LSD or placebo) and subject (S1-24). Calibrators, controls and subject samples were thawed once, and 100 μL aliquots was taken to minimize the freeze-thaw cycles. To 100 μL of plasma, 110 μL of an acetonitrile/ LSD-d 3 solution (0.01 μg/mL) was added. The samples were then vigorously vortexed and centrifuged for 10 minutes at 13 200 g, and the supernatant was then transferred to 96-well plates.
| Experiments
| Calibration
Six calibration standards were prepared by spiking plasma samples with LSD, iso-LSD, and nor-LSD to concentrations of 0.05, 0.1, 0.5, 1, 5, and 10 ng/mL plus blank (matrix only) and zero sample (matrix plus internal standard). Five calibrators were used for O-H-LSD with concentrations of 0.05, 0.1, 0.5, 1, 5, and 10 ng/mL plus blank (matrix only) and zero sample (matrix plus internal standard). The highest calibration point in plasma was adopted from our previously developed method and pharmacokinetic-pharmacodynamic data. 12, 21 The calibration curves were linearly fitted using a weighting factor of 1/x 2 .
| Selectivity
Following U.S. Food and Drug Administration validation guidelines, 26 we collected plasma samples from six different healthy volunteers and tested them for interference to establish selectivity. We further analyzed samples from the placebo condition to confirm the absence of LSD.
| Matrix effects and recovery
Matrix effects, recovery, and process efficiency were measured and calculated according to Matuszewski et al. 27 In regard of the vulnerability to light and air and because of the online extraction that was used in the present method, the extraction step comprised only pro- were calculated as the areas of standards that were spiked before extraction divided by the areas of standards that were spiked after extraction. The process efficiency was adopted from Matuszewski et al. 27 and calculated as the ratio between the area of the standard spiked before extraction and the areas of the standard in neat solution.
| Stability
The determination of long-term stability was based on Li et al. and
Klette et al., in which LSD is regarded as stable under storage conditions of −20°C. 28, 29 However, LSD is known to be very unstable and vulnerable to air, light, and heat. Even ambient temperature (20-25°C) and normal light conditions can lead to a decrease in LSD concentrations. Therefore, we assessed bench-top stability and autosampler stability with multiple measurements of calibration and QC samples within 24 h. For autosampler stability, the samples were kept in lightprotected, sealed, 96-well deep-well plates at 4°C in the autosampler until injection. During the study, the samples were drawn through an intravenous catheter into lithium-heparin tubes and directly F I G U R E 1 Structure, retention time, ion transitions, and collision energies of lysergic acid diethylamide (LSD) and selected metabolites
13/14-hydroxy-LSD 2-oxo-LSD Lysergic-acid-ethyl-hydroxyethylamide (LEO) Lysergic-acid-monoethylamide (LAE) (1), iso-LSD (2), nor-LSD (3) and 2-oxo-3-hydroxy-LSD (4), lysergic-acid monoethylamide (5), lysergic-acid-ethyl-2-hydroxyethylamide (6), 13/14-hydroxy-LSD (7), and 2-oxo-LSD (8) centrifuged, and the plasma was stored at −20°C at the study site before transferring to the laboratory for analysis. Due to the known vulnerability of LSD, calibrators and quality controls were freshly weighted every week and single aliquots were stored at −20°C. A new calibration was run every day and with every study subject.
| Lower limits of detection and quantification
Drug-free plasma samples were spiked with different concentrations of LSD, iso-LSD, O-H-LSD, and nor-LSD for determination of the limit of quantification (LOQ) and the limit of detection (LOD). The LOQ concentrations had to give a response at least five times greater than the blank. In addition, precision had to be <20%, and accuracy had to be 80%-120% using at least five determinations per matrix and concentration. The LOD concentration was determined as the lowest discriminable peak in the region of a signal-to-noise ratio greater than five.
| Carryover
For the determination of the carryover, different blank plasma samples were run between patient samples, highest calibrations, and quality controls.
| Reproducibility
According to U.S. Food and Drug Administration guidelines, 26 the reproducibility of quantification was determined by measuring each QC sample five times in 1 day to establish intraday precision and accuracy. Each QC sample was also measured for five consecutive days to determine interday precision and accuracy. All of the values had to meet the criteria of a coefficient of variation (CV) <15%, response <20% at the LOQ, and accuracy of 80%-120%. To demonstrate the accuracy and precision of the method, we used three QCs (low, medium, and high). The QC concentrations were 0.05, 1, and 10 ng/mL for LSD, iso-LSD, and nor-LSD, and 0.1, 1, and 10 ng/mL for O-H-LSD, respectively.
| RESULTS
Lysergic acid diethylamide, LSD-d 3 , iso-LSD, and the metabolites nor-LSD, LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD (glucuronides) eluted between 4 and 11 minutes. The chromatographic separation of spiked samples and selected metabolites is depicted in Figure 2A , and the chromatogram of a subject's sample 4 h after LSD administration is presented in Figure 2B .
| Selectivity
None of the six plasma samples showed any interference within the measured mass range and time frame (Figure 3) . Furthermore, none of the measured plasma samples from the placebo condition showed any interference.
| Matrix effects and recovery
The plasma matrix effects were 125% for LSD, 119% for iso-LSD,
103% for O-H-LSD, and 118% for nor-LSD at concentrations of
10 ng/mL, consistent with a slight ion enhancement for LSD, iso-LSD, and nor-LSD. Recoveries were calculated as 70%-90% for all substances at 10 ng/mL. Process efficiencies were 113% for LSD, 86%
for iso-LSD, 77% for O-H-LSD, and 93% for nor-LSD.
| Stability
The concentrations of the processed samples decreased up to −60% within 24 hours at ambient temperature (20-23°C). The concentrations of the extracted and sealed plasma samples that
Chromatogram of 6 blank plasma samples from six different subjects, and a blank sample containing lysergic acid diethylamide-d3 were stored within the closed autosampler at 4°C were stable up to 24 hours.
| Lower limits of detection and quantification
The LOQ was 0.05 ng/mL for LSD, iso-LSD, and nor-LSD. For O-H-LSD, the respective concentration was 0.1 ng/mL. The LODs were 0.01 ng/mL for all compounds.
| Carryover
No carryover was found for LSD, iso-LSD, O-H-LSD, or nor-LSD in the plasma samples. Despite these results as a preventive measure, a consecutive blank was always run after the highest calibrator (10 ng/ mL) and QC (10 ng/mL) during method development and the measurement of the study samples.
| Linearity
Calibration curves in plasma were linear over the respective calibration ranges, with a mean correlation coefficient (R 
| Reproducibility
All of the substances fulfilled the accuracy and precision criteria. The mean intraday accuracy and precision were 105% and 4.81% for LSD, 98.7% and 5.75% for iso-LSD, 106% and 4.54% for O-H-LSD, and 107% and 5.82% for nor-LSD, respectively. The mean interday accuracy and precision were 105% and 4.35% for LSD, 99.4% and 7.21%
for iso-LSD, 99.4% and 7.21% for O-H-LSD, and 102% and 5.88% for nor-LSD, respectively.
| Identification of non-commercially available LSD metabolites
Lysergic acid diethylamide metabolites were extracted by liquid-liquid extraction from pooled LSD-positive 24-h urine samples (8 L) to reach high concentrations. One part of the concentrated metabolites was kept for eventual quantification, and the second part was extracted using industrial separation by automated thin-layer chromatography and purification. Separation was performed with generous support from Camag (Muttenz, Switzerland). Parent masses and selected transitions for LC-MS were adopted from Cai et al. 22 and Canezin et al. 23 and replicated by injecting a mixture of the concentrated, extracted metabolites. All of the identified metabolites from concentrated urine samples (LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD) were added to the quantification method before validation, for qualitative screening of the study samples.
| Samples
LSD (100 μg) and placebo were administered to 24 healthy subjects Table   1 ). Nor-LSD could only be quantified in two subjects (3 and 4 hours post-administration), and LAE, LEO, 2-oxy LSD, and 13/14-hydroxy-LSD were detected in some of the samples. 13/14-hydroxy-LSD glucuronides were undetectable because they were cleaved during ionization. Detailed study descriptions, pharmacokinetic data, and pharmacokinetic-pharmacodynamic analyses will be published elsewhere.
| DISCUSSION AND CONCLUSION
With mean maximum plasma concentrations of LSD of ~1 ng/mL, the 
